In 2002 he became a member of the SIOPEN group and got involved in the clinical development of a monoclonal antibody directed against ganglioside GD2 (ch14.18/CHO).
Seit der Mitgliedschaft in der SIOPEN-Gruppe 2002 wirkt Lode in der klinischen Entwicklung eines monoklonalen Antikörpers gegen Gangliosid GD2 (ch14.18/CHO) mit.